BTP Viewed As Glomerular Filtration Rate Marker
|
By LabMedica International staff writers Posted on 24 Apr 2018 |

Image: The N Latex Cystatin C Assay for the detection of decline in renal function (Photo courtesy of Siemens Healthcare).
Beta Trace Protein (BTP) is a promising marker of glomerular filtration rate (GFR) as it was reported to be increased in the serum of patients with renal disease. Some evidence suggests that it is more sensitive than creatinine (Cr) at detecting early changes in GFR.
Unlike Cr, very little is known about the origin and metabolism of BTP. BTP is a heterogeneous glycoprotein with multiple isoforms and is present in various fluid compartments including blood, urine and cerebral spinal fluid (CSF). The impact of hepatic dysfunction on serum BTP concentrations has recently been investigated.
Scientists at Queen’s University (Kingston, ON, Canada) and their colleagues conducted a case-control study between June to October 2014 of 99 cirrhotic subjects and matched controls. The diagnosis of cirrhosis was confirmed by the hepatologists according to standard clinical criteria including non-invasive testing estimating F4 fibrosis in an individual with known chronic liver disease. Basic demographic, clinical and laboratory data were collected including diabetes status, etiology of cirrhosis, presence of ascites or encephalopathy, INR, albumin and bilirubin.
The team measured Cystatin C (cysC), BTP using nephelometry assays and Cr using a Vitros Chemistry enzymatic assay. The BTP/cysC ratio was calculated for each subject. The BTP/cysC ratio was chosen in lieu of the BTP/Cr ratio due to the well-recognized inaccuracy of serum creatinine as a marker of GFR in the setting of hepatic dysfunction.
The investigators found there were no differences in BTP/cysC ratios between cases and controls for the entire cohort. However there were significant differences between cases (1.09) and controls (0.73) for the BTP/Cr ratios. The BTP/Cr ratio was higher in those with more advanced cirrhosis as compared to those with less severe cirrhosis (1.20 versus 1.03). There were no differences in BTP/cysC ratios between those with less severe and more advanced cirrhosis.
The authors concluded that their study suggests that hepatic dysfunction does not influence serum BTP levels and argues against a significant role for the liver in BTP metabolism. It is well recognized that a number of factors (muscle mass, diet, hepatic function) influence serum Cr independently of GFR and these contribute significantly to the difficulties in accurately assessing GFR using Cr. The study was published on April 13, 2018, in the journal BMC Nephrology.
Related Links:
Queen’s University
Unlike Cr, very little is known about the origin and metabolism of BTP. BTP is a heterogeneous glycoprotein with multiple isoforms and is present in various fluid compartments including blood, urine and cerebral spinal fluid (CSF). The impact of hepatic dysfunction on serum BTP concentrations has recently been investigated.
Scientists at Queen’s University (Kingston, ON, Canada) and their colleagues conducted a case-control study between June to October 2014 of 99 cirrhotic subjects and matched controls. The diagnosis of cirrhosis was confirmed by the hepatologists according to standard clinical criteria including non-invasive testing estimating F4 fibrosis in an individual with known chronic liver disease. Basic demographic, clinical and laboratory data were collected including diabetes status, etiology of cirrhosis, presence of ascites or encephalopathy, INR, albumin and bilirubin.
The team measured Cystatin C (cysC), BTP using nephelometry assays and Cr using a Vitros Chemistry enzymatic assay. The BTP/cysC ratio was calculated for each subject. The BTP/cysC ratio was chosen in lieu of the BTP/Cr ratio due to the well-recognized inaccuracy of serum creatinine as a marker of GFR in the setting of hepatic dysfunction.
The investigators found there were no differences in BTP/cysC ratios between cases and controls for the entire cohort. However there were significant differences between cases (1.09) and controls (0.73) for the BTP/Cr ratios. The BTP/Cr ratio was higher in those with more advanced cirrhosis as compared to those with less severe cirrhosis (1.20 versus 1.03). There were no differences in BTP/cysC ratios between those with less severe and more advanced cirrhosis.
The authors concluded that their study suggests that hepatic dysfunction does not influence serum BTP levels and argues against a significant role for the liver in BTP metabolism. It is well recognized that a number of factors (muscle mass, diet, hepatic function) influence serum Cr independently of GFR and these contribute significantly to the difficulties in accurately assessing GFR using Cr. The study was published on April 13, 2018, in the journal BMC Nephrology.
Related Links:
Queen’s University
Latest Immunology News
- Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
- Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
- Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways
- Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel
- Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
- Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
- Compact Immunoanalyzer Gains CE Mark for Testing Across Local Care Settings
- COVID-19 and Flu Combo Test Launches With FDA Clearance
- Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
- Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
- Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
- Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
- Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
- FDA Approval Adds Automated Testing Option for Parvovirus B19 Serology
- Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier
- Blood-Based Immune Signal Could Reveal Lung Cancer Risk Before Tumors Develop
Channels
Clinical Chemistry
view channel
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreFDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
Clinical laboratories use mass spectrometry for applications requiring highly sensitive and specific measurement, including steroid hormone measurement, vitamin D testing, and therapeutic drug monitoring.... Read moreMolecular Diagnostics
view channel
Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreMicrobiology
view channel
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







